Sydney - Thursday - August 28: (RWE Australian Business News) -
Progen Pharmaceuticals (ASX:PGL) reports a strong cash balance of $76.7m
and net tangible assets of $1.19 per share.
The consolidated loss for the year totalled $26.1m (2007:
$22.5m) on operating revenues of $7.8m (2007: $3.8m). The loss was
impacted by a $3.8m unrealised foreign currency charge due to the
Company holding significant USD cash and cash equivalents and $4.0m
being expensed in relation to the unwind of the Medigen strategic
alliance.
Sydney - Thursday - August 28: (RWE Australian Business News)...
Add to My Watchlist
What is My Watchlist?